Sterling Capital Management
ORMP icon

Sterling Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Sterling Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.13K Sell
671
-15
-2% -$68 ﹤0.01% 3045
2026
Q2 		$3.3K Buy
+686
New +$2.73K ﹤0.01% 2819

Other funds holding ORMP

Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
SCM
Sage Capital Management Stockton, New Jersey $263M AUM 22.29% 1-Year Est. Return
Redwood Family Wealth
Redwood Family Wealth Addison, Texas $113M AUM 24.54% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Sterling Capital Management's ORMP Position: Q3 2026 in Review

Sterling Capital Management reduced its Oramed Pharmaceuticals (ORMP) stake by 2.2% in Q3 2026, selling an estimated $68 and leaving 671 shares worth $3.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Sterling Capital Management first reported a position in ORMP in Q2 2026 and has held it in 2 quarters since. The position peaked at $3.3K in Q2 2026. 10 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

  • Sterling Capital Management held 671 shares of Oramed Pharmaceuticals worth $3.13K as of Q3 2026.
  • Sterling Capital Management sold 15 Oramed Pharmaceuticals shares in Q3 2026, an estimated $68.
  • Oramed Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3045 holding.
  • Sterling Capital Management first reported a position in Oramed Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Sterling Capital Management's Oramed Pharmaceuticals position peaked at $3.3K in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.